Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-09-12 Sale | 2024-09-13 6:22 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 64,857 | $2.647 | $171,678 | 3,413,581 (Indirect) | View |
| 2024-09-11 Sale | 2024-09-12 8:40 pm | GENELUX Corp | GNLX | Tyree James L Director | 1,730 | $2.6005 | $4,499 | 47,521 (Direct) | View |
| 2024-09-09 Sale | 2024-09-11 6:23 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 75,143 | $2.6165 | $196,609 | 3,478,438 (Indirect) | View |
| 2024-09-03 Sale | 2024-09-06 5:08 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 42,818 | $2.0929 | $89,614 | 3,553,581 (Indirect) | View |
| 2024-08-28 Sale | 2024-08-30 7:58 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 265,552 | $2.0878 | $554,411 | 3,596,399 (Indirect) | View |
| 2024-08-23 Sale | 2024-08-27 7:23 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 91,630 | $2.1857 | $200,278 | 3,861,951 (Indirect) | View |
| 2024-06-24 Sale | 2024-07-08 4:30 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 6,849 | $2.12 | $14,520 | 10,869 (Direct) | View |
| 2024-06-24 Sale | 2024-07-08 4:30 pm | GENELUX Corp | GNLX | Ryder Sean General Counsel | 5,496 | $2.12 | $11,652 | 19,388 (Direct) | View |
| 2024-06-24 Sale | 2024-07-08 4:30 pm | GENELUX Corp | GNLX | Jewett Caroline Head of Quality | 4,961 | $2.12 | $10,517 | 16,174 (Direct) | View |
| 2024-05-29 Purchase | 2024-06-07 9:45 pm | GENELUX Corp | GNLX | Tyree James L Director | 6,250 | $0 | $0 | 15,960 (Direct) | View |
| 2024-05-29 Purchase | 2024-06-07 9:45 pm | GENELUX Corp | GNLX | Smither John W Director | 6,250 | $0 | $0 | 19,420 (Direct) | View |
| 2024-05-29 Purchase | 2024-06-07 9:45 pm | GENELUX Corp | GNLX | Thomas John Director | 2,500 | $0 | $0 | 468,460 (Direct) | View |
| 2024-05-29 Purchase | 2024-06-07 9:45 pm | GENELUX Corp | GNLX | Mirabelli Mary Director | 8,000 | $0 | $0 | 20,460 (Direct) | View |
| 2024-05-29 Purchase | 2024-06-07 9:40 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 2,500 | $0 | $0 | 5,000 (Direct) | View |
| 2024-05-29 Purchase | 2024-06-07 9:40 pm | GENELUX Corp | GNLX | Zindrick Thomas President and CEO | 200,000 | $0 | $0 | 414,651 (Indirect Direct) | View |
| 2024-05-29 Purchase | 2024-06-07 9:40 pm | GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory | 1,250 | $0 | $0 | 14,565 (Direct) | View |
| 2024-05-29 Purchase | 2024-06-07 9:40 pm | GENELUX Corp | GNLX | Ryder Sean General Counsel | 10,000 | $0 | $0 | 20,572 (Direct) | View |
| 2024-05-29 Purchase | 2024-06-07 9:40 pm | GENELUX Corp | GNLX | Zak Lourie S. Chief Financial Officer | 31,250 | $0 | $0 | 62,500 (Direct) | View |
| 2024-05-13 Sale | 2024-05-15 5:59 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 35,966 | $3.625 | $130,377 | 3,953,581 (Indirect) | View |
| 2024-05-07 Sale | 2024-05-09 4:38 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 19,944 | $3.7756 | $75,300 | 3,989,547 (Indirect) | View |
| 2024-04-29 Sale | 2024-05-01 6:16 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 59,999 | $3.2323 | $193,934 | 4,009,491 (Indirect) | View |
| 2024-04-22 Sale | 2024-04-24 5:50 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 44,395 | $3.506 | $155,647 | 4,069,490 (Indirect) | View |
| 2024-04-16 Sale | 2024-04-18 5:00 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 71,420 | $3.5876 | $256,227 | 4,113,885 (Indirect) | View |
| 2023-12-15 Sale | 2023-12-18 4:15 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 32,535 | $13.16 | $428,180 | 0 (Direct) | View |
| 2023-12-13 Sale | 2023-12-14 8:59 pm | GENELUX Corp | GNLX | Tyree James L Director | 9,000 | $13.22 | $118,969 | 3,460 (Direct) | View |
| 2023-12-13 Sale | 2023-12-14 8:58 pm | GENELUX Corp | GNLX | Thomas John Director | 9,000 | $13.38 | $120,387 | 463,460 (Direct) | View |
| 2023-12-07 Sale | 2023-12-08 5:57 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 36,800 | $11.85 | $435,995 | 32,535 (Direct) | View |
| 2023-11-21 Sale | 2023-11-22 4:15 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 18,665 | $10.26 | $191,555 | 69,335 (Direct) | View |
| 2023-11-17 Sale | 2023-11-21 4:15 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 18,135 | $11.6 | $210,431 | 88,000 (Direct) | View |
| 2023-10-25 Sale | 2023-10-26 5:07 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 5,704 | $19.4 | $110,638 | 4,185,305 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-10-18 Option Award | 2024-10-21 5:05 pm | N/A 2034-10-17 | GENELUX Corp | GNLX | Scigalla Paul Chief Medical Officer | 33,332 | $0 | 33,332 (Direct) | View |
| 2024-08-01 Option Award | 2024-08-05 6:37 pm | N/A 2034-07-31 | GENELUX Corp | GNLX | Tyree James L Director | 90,010 | $0 | 99,720 (Direct) | View |
| 2024-08-01 Option Award | 2024-08-05 6:36 pm | N/A 2034-07-31 | GENELUX Corp | GNLX | Mirabelli Mary Director | 90,010 | $0 | 102,470 (Direct) | View |
| 2024-08-01 Option Award | 2024-08-05 6:35 pm | N/A 2034-07-31 | GENELUX Corp | GNLX | Thomas John Director | 90,010 | $0 | 555,970 (Direct) | View |
| 2024-08-01 Option Award | 2024-08-05 6:34 pm | N/A 2034-07-31 | GENELUX Corp | GNLX | Smither John W Director | 90,010 | $0 | 103,180 (Direct) | View |
| 2024-02-19 Option Award | 2024-07-08 4:30 pm | N/A N/A | GENELUX Corp | GNLX | Zindrick Thomas President and CEO | 34,584 | $0 | 50,207 (Direct) | View |
| 2024-02-19 Option Award | 2024-07-08 4:30 pm | N/A N/A | GENELUX Corp | GNLX | Zak Lourie S. Chief Financial Officer | 5,072 | $0 | 38,428 (Direct) | View |
| 2024-02-19 Option Award | 2024-07-08 4:30 pm | N/A N/A | GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory | 2,723 | $0 | 18,144 (Direct) | View |
| 2024-02-19 Option Award | 2024-07-08 4:30 pm | N/A N/A | GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development | 15,218 | $0 | 20,953 (Direct) | View |
| 2024-02-19 Option Award | 2024-07-08 4:30 pm | N/A N/A | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 15,218 | $0 | 10,869 (Direct) | View |
| 2024-02-19 Option Award | 2024-07-08 4:30 pm | N/A N/A | GENELUX Corp | GNLX | Ryder Sean General Counsel | 12,206 | $0 | 19,388 (Direct) | View |
| 2024-02-19 Option Award | 2024-07-08 4:30 pm | N/A N/A | GENELUX Corp | GNLX | Jewett Caroline Head of Quality | 4,755 | $0 | 16,174 (Direct) | View |